You are viewing: Mexico Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Mexico Nuclear Medicine Market was valued at $135.5 Million in 2025 and projected to reach to $210 Million by 2030, representing a compound annual growth rate of 9.2%. Mexico's nuclear medicine market is positioned for sustained growth through 2030, driven by increasing healthcare expenditures and the rising prevalence of chronic diseases requiring advanced diagnostic imaging.

Mexico Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Nuclear Medicine Market Trends and Insights

  • This 9.2% compound annual growth rate reflects Mexico's increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures across healthcare facilities.
  • Mexico's market expansion is driven by rising healthcare investments, growing prevalence of chronic diseases, and improved access to nuclear medicine technologies in major urban centers. The nuclear medicine sector in Mexico benefits from enhanced regulatory frameworks and collaborations between public and private healthcare institutions.
  • Mexico's market growth trajectory, while moderating compared to global rates, demonstrates the country's commitment to modernizing its diagnostic capabilities.
  • Between 2025 and 2030, Mexico is expected to strengthen its position as a regional hub for nuclear medicine services, supported by infrastructure development and clinical expertise expansion throughout the country..

Key Market Statistics

  • CAGR (2025-2030) 9.2% CAGR
  • Market Size, 2025 ~USD 135.5 Million
  • Forecast, 2030 ~USD 210 Million
  • Country Mexico

Mexico Nuclear Medicine Market Overview

Market Valuation :

Mexico's nuclear medicine market is valued at $135.5 million in 2025, with projections reaching $210.0 million by 2030, representing a robust 9.2% CAGR over the forecast period.

Growth Drivers :

Rising healthcare investments and increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures across Mexican healthcare facilities are propelling market expansion.

Regional Performance :

Mexico's 9.2% CAGR demonstrates steady market growth, though it trails the global nuclear medicine market CAGR of 15.1%, indicating room for accelerated adoption.

Healthcare Infrastructure :

Growing modernization of Mexican healthcare facilities and enhanced access to advanced diagnostic and therapeutic nuclear medicine technologies are strengthening market fundamentals.

Mexico Nuclear Medicine Market Dynamics

  • Healthcare providers across Mexico are progressively integrating nuclear medicine procedures into their service offerings, supported by improved reimbursement policies and patient awareness.
  • The market's 9.2% CAGR reflects Mexico's commitment to modernizing its healthcare infrastructure and expanding access to cutting-edge diagnostic and therapeutic solutions.
  • Continued investment in medical technology and training of nuclear medicine professionals will further accelerate market penetration across urban and emerging healthcare centers throughout the country..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Mexico's nuclear medicine market is valued at $135.5 million in 2025 and will reach $210.0 million by 2030, representing a 9.2% CAGR.
    • Mexico's market growth is driven by increased healthcare spending, rising chronic disease prevalence, and expanded access to diagnostic imaging technologies.
    • Mexico's nuclear medicine sector benefits from regulatory improvements and public-private healthcare partnerships strengthening service delivery.
    • Mexico is positioned as a growing regional center for nuclear medicine in Latin America, with infrastructure and clinical capacity expanding through 2030.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    Mexico Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    MEXICO: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES11.1121314.115.316.61819.58.4
    DIAGNOSTIC & IMAGING CENTERS30.83437.541.445.750.455.561.110.2
    HOSPITALS68.474.481.188.396.2104.7113.9123.78.8
    OTHER END USERS3.43.63.94.24.64.95.35.77.8
    TOTAL113.6124.1135.5148.1161.7176.6192.72109.2

    Target Audience

    • Medical Device Manufacturers : Need Mexico-specific market sizing and growth forecasts to evaluate market potential, plan product launches, and allocate sales resources effectively in this emerging nuclear medicine market.
    • Healthcare Facility Operators : Require insights on market trends, technology adoption rates, and investment opportunities to make informed decisions about nuclear medicine service expansion and equipment procurement in Mexico.
    • Investment & Private Equity Firms : Seek detailed Mexico market analysis and growth projections to identify investment opportunities, assess portfolio company potential, and evaluate acquisition targets in the healthcare sector.
    • Healthcare Consultants & Advisors : Need country-specific market data and forecasts to provide strategic recommendations to clients operating in or entering Mexico's nuclear medicine and diagnostic imaging markets.
    • Government & Policy Makers : Require market intelligence on Mexico's nuclear medicine sector to inform healthcare policy decisions, infrastructure investments, and regulatory frameworks supporting medical technology adoption.

    Reasons to Buy this Report

    • Market Size & Growth Trajectory : Gain precise valuation data for Mexico's nuclear medicine market ($135.5M in 2025) with detailed 5-year forecasts to 2030, enabling accurate investment planning and revenue projections.
    • Competitive Intelligence : Understand Mexico-specific market dynamics, healthcare infrastructure developments, and adoption rates to identify competitive advantages and market entry opportunities in this growing segment.
    • Strategic Planning : Leverage country-specific insights on healthcare investments, regulatory environment, and technology adoption patterns to develop targeted expansion strategies for Mexico's nuclear medicine sector.
    • Investment Decision Support : Access comprehensive Mexico market analysis to support capital allocation decisions, partnership evaluations, and business development initiatives in the nuclear medicine space.
    • Stakeholder Alignment : Present data-driven Mexico market forecasts and growth drivers to investors, board members, and stakeholders to justify strategic initiatives and resource commitments in this market.

    Frequently asked questions

    What is the current size of Mexico's nuclear medicine market?

    Mexico's nuclear medicine market is estimated at $135.5 million in 2025 and is projected to grow to $210.0 million by 2030.

    What is the growth rate of Mexico's nuclear medicine market?

    Mexico's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2025 to 2030.

    What factors are driving growth in Mexico's nuclear medicine market?

    Mexico's market growth is driven by increased healthcare investments, rising prevalence of chronic diseases, improved regulatory frameworks, and expanded access to nuclear medicine technologies across the country.

    How does Mexico's nuclear medicine market compare to the global market?

    Mexico's nuclear medicine market is growing at 9.2% CAGR, which is below the global average of 15.1%, reflecting regional market maturity and healthcare infrastructure development patterns.

    What is the forecast for Mexico's nuclear medicine market by 2030?

    Mexico's nuclear medicine market is forecasted to reach $210.0 million by 2030, representing a $74.5 million increase from the 2025 baseline of $135.5 million.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status